Innate immunity: the first line of defense against SARS-CoV-2
Abstract The coronavirus disease 2019 (COVID-19) pandemic, caused by severe acute
respiratory syndrome coronavirus (SARS-CoV)-2, continues to cause substantial morbidity …
respiratory syndrome coronavirus (SARS-CoV)-2, continues to cause substantial morbidity …
Traumatic brain injury: progress and challenges in prevention, clinical care, and research
Executive summary Traumatic brain injury (TBI) has the highest incidence of all common
neurological disorders, and poses a substantial public health burden. TBI is increasingly …
neurological disorders, and poses a substantial public health burden. TBI is increasingly …
[HTML][HTML] Features, evaluation, and treatment of coronavirus (COVID-19)
M Cascella - 2020 - ncbi.nlm.nih.gov
Objectives: Screen individuals based on exposure and symptom criteria to identify potential
COVID-19 cases. Identify the clinical features and radiological findings expected in patients …
COVID-19 cases. Identify the clinical features and radiological findings expected in patients …
[HTML][HTML] Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
RECOVERY Collaborative Group - Lancet (London, England), 2021 - ncbi.nlm.nih.gov
Background In this study, we aimed to evaluate the effects of tocilizumab in adult patients
admitted to hospital with COVID-19 with both hypoxia and systemic inflammation. Methods …
admitted to hospital with COVID-19 with both hypoxia and systemic inflammation. Methods …
[HTML][HTML] Emerging variants of SARS-CoV-2 and novel therapeutics against coronavirus (COVID-19)
A Aleem, AS Ab, AK Slenker - 2021 - europepmc.org
Objectives: Describe the clinical manifestations, including extrapulmonary manifestations of
COVID-19. Outline the latest treatments available in the management of COVID-19 …
COVID-19. Outline the latest treatments available in the management of COVID-19 …
Early treatment of COVID-19 with anakinra guided by soluble urokinase plasminogen receptor plasma levels: a double-blind, randomized controlled phase 3 trial
Early increase of soluble urokinase plasminogen activator receptor (suPAR) serum levels is
indicative of increased risk of progression of coronavirus disease 2019 (COVID-19) to …
indicative of increased risk of progression of coronavirus disease 2019 (COVID-19) to …
A guide to immunotherapy for COVID-19
FL van de Veerdonk, E Giamarellos-Bourboulis… - Nature medicine, 2022 - nature.com
Immune dysregulation is an important component of the pathophysiology of COVID-19. A
large body of literature has reported the effect of immune-based therapies in patients with …
large body of literature has reported the effect of immune-based therapies in patients with …
Association between administration of IL-6 antagonists and mortality among patients hospitalized for COVID-19: a meta-analysis
Importance Clinical trials assessing the efficacy of IL-6 antagonists in patients hospitalized
for COVID-19 have variously reported benefit, no effect, and harm. Objective To estimate the …
for COVID-19 have variously reported benefit, no effect, and harm. Objective To estimate the …
Infectious Diseases Society of America Guidelines on the treatment and management of patients with COVID-19 (April 2020)
Background There are many pharmacologic therapies that are being used or considered for
treatment of coronavirus disease 2019 (COVID-19). There is a need for frequently updated …
treatment of coronavirus disease 2019 (COVID-19). There is a need for frequently updated …
[HTML][HTML] The first 12 months of COVID-19: a timeline of immunological insights
Since the initial reports of a cluster of pneumonia cases of unidentified origin in Wuhan,
China, in December 2019, the novel coronavirus that causes this disease—severe acute …
China, in December 2019, the novel coronavirus that causes this disease—severe acute …